Trial Profile

A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Nov 2025 Planned End Date changed from 1 Feb 2026 to 1 Jan 2027.
12 Nov 2025 Planned primary completion date changed from 1 Feb 2026 to 1 Jan 2027.
02 Oct 2025 According to an Edgewise Therapeutics Media Release, company announced its participation at the 30th International Annual Congress of the World Muscle Society (WMS). Scientific Posters includes LYNX Phase 2 trial results in DMD: Positive effects of sevasemten, an investigational agent, on physical function defines dose and informs design for Phase 3 (730LBP).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com